AXIM BIOTECHNOLOGIES, INC. | 2013 | FY | 3


Note 9 - Going Concern

 

As noted, the Company has concentrations in Geographic area and product currently available.  Additionally the Company has no projected future license fees and is committed to purchase and install an APS200 system before December 31, 2014.  The culmination of that effort is dependent on the Company's ability to raise capital either by borrowing under convertible notes (Note 4) or by a combination of borrowing and the acquisition of funds by its joint venture partner and licensee.  Any failure of these conditions could cause the Company to cease operations during the next year.


us-gaap:LiquidityDisclosureGoingConcernNote